The Orthopaedic Implant Company Inc.01.29.16
Reno, Nev.-based The Orthopaedic Implant Company Inc. (OIC) has released its intramedullary (IM) hip nail system. The company reports that the device has been approved by the U.S. Food and Drug Administration.
The OIC hip nail system consists of short and long nails with a pre-loaded cannulated set screw, 10.5 mm lag screws, and 5.0mm cross-lock screws. The long nails feature a 1 meter bow for better anatomic fit. The system is designed to achieve optimal stability upon fracture reduction and fixation, while a full carbon fiber targeter provides for unobstructed views under fluoroscopy.
Consistent with OIC’s existing portfolio of implants, the OIC hip nail system has been created in response to U.S. healthcare’s demand for better value to ensure its sustainability and uncompromising clinical outcomes.
“We have been really excited to launch this system,” said Todd Martens, vice president of product design and development. “Hip fractures are the most commonly occurring fracture patterns. Being able to offer state of the art technology at a fraction of the cost of conventional vendors will have a profound impact on our country’s healthcare spend.”
The OIC hip nail system consists of short and long nails with a pre-loaded cannulated set screw, 10.5 mm lag screws, and 5.0mm cross-lock screws. The long nails feature a 1 meter bow for better anatomic fit. The system is designed to achieve optimal stability upon fracture reduction and fixation, while a full carbon fiber targeter provides for unobstructed views under fluoroscopy.
Consistent with OIC’s existing portfolio of implants, the OIC hip nail system has been created in response to U.S. healthcare’s demand for better value to ensure its sustainability and uncompromising clinical outcomes.
“We have been really excited to launch this system,” said Todd Martens, vice president of product design and development. “Hip fractures are the most commonly occurring fracture patterns. Being able to offer state of the art technology at a fraction of the cost of conventional vendors will have a profound impact on our country’s healthcare spend.”